I'll research this company before writing the profile.
Actavis is the name carried by two linked generic-drug businesses rather than one continuous company. The original Actavis Group was founded in 1956 and headquartered in Iceland, grew into a generics manufacturer with roughly 10,000 employees across some 40 countries, and was taken private by Novator in 2007. U.S.-based Watson Pharmaceuticals, Inc. (founded 1984 in Corona, California) acquired Actavis Group in 2012 and renamed itself Actavis, Inc. in January 2013, then re-domiciled as Ireland-based Actavis plc (NYSE: ACT).
Operations. Actavis developed, manufactured, and sold generic pharmaceuticals — oral solids, injectables, transdermals, and oral contraceptives — and later added branded products and biosimilars through acquisition. Actavis plc bought Warner Chilcott (2013), Forest Laboratories (2014, about $25 billion), and Allergan (2015, about $66 billion), then adopted the Allergan name. In 2016 Teva Pharmaceutical Industries acquired the Actavis generics business for $40.5 billion; the Actavis brand continues on generics sold by Teva. Actavis was a large-cap public company, with market value above $100 billion during 2015.
Litigation posture. Pure defendant: one tracked case, zero as plaintiff. That profile fits an operating generics manufacturer defending brand-holder Hatch-Waxman suits, not an NPE asserting an acquired portfolio. The sole case sits in the District of New Jersey — the standard venue for ANDA litigation — not a plaintiff-friendly Eastern District of Texas docket.
Notable case. Celgene Corp. v. Natco Pharma Ltd. et al. (D.N.J., filed Oct. 8, 2010). Celgene sued over ANDAs for generic REVLIMID (lenalidomide), asserting composition-of-matter, polymorph, and drug-distribution patents. The docket names Natco Pharma, Arrow International, and Watson Laboratories — the generics subsidiary that became an Actavis entity after the 2013 renaming. The consolidated action settled in January 2016 by consent judgment permitting Natco a volume-limited U.S. launch in 2022 and full generic entry on January 31, 2026.
Note: because "Actavis" applied to successive corporate entities, individual case records may reflect Watson's later renaming to Actavis.